US 10155011
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
granted A61KA61K2239/48A61K35/00
Quick answer
US patent 10155011 (Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases) held by Sangamo Therapeutics, Inc. expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2239/48, A61K35/00, A61K35/28, A61K38/00